US equities
|
MU
$987.88
▼-4.00%
META
$743.91
▲+3.51%
NVDA
$226.50
▼-1.21%
SNDK
$1,483.02
▼-6.25%
SPCX
$163.92
▲+0.83%
AMD
$590.01
▼-2.97%
MSFT
$540.23
▲+0.96%
TSLA
$378.79
▼-1.02%
MU
$987.88
▼-4.00%
META
$743.91
▲+3.51%
NVDA
$226.50
▼-1.21%
SNDK
$1,483.02
▼-6.25%
SPCX
$163.92
▲+0.83%
AMD
$590.01
▼-2.97%
MSFT
$540.23
▲+0.96%
TSLA
$378.79
▼-1.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
34.71
-0.73 (-2.06%)
Delayed Quote
Updated: 3:22 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roivant Sciences Ltd. - Common Shares
< Previous
1
2
3
4
Next >
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
September 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From
Roivant Sciences
Via
GlobeNewswire
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
September 06, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
September 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From
Roivant Sciences
Via
GlobeNewswire
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
August 26, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
August 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
August 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026
From
Roivant Sciences
Via
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
March 03, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
February 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
February 06, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
February 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
December 11, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
November 10, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
October 27, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
September 17, 2025
From
Roivant Sciences
Via
GlobeNewswire
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
September 11, 2025
From
Roivant Sciences
Via
GlobeNewswire
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
September 04, 2025
From
Pulmovant, Inc.
Via
GlobeNewswire
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
September 03, 2025
From
Roivant Sciences
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
